Regulation

EMA starts booster dose data evaluation for Pfizer-BioNTech Covid-19 vaccine

The European Medicines Agency (EMA) has started evaluation of the data on a booster (third) dose for the Covid-19 vaccine, Comirnaty, developed by Pfizer and BioNTech.

US FDA accepts Teva-MedinCell’s new drug application for drug to treat schizophrenia

Teva Pharmaceuticals and MedinCell’s new drug application (NDA) for their drug, TV-46000/mdc-IRM to treat schizophrenia has been accepted by the US Food and Drug Administration (FDA).

US FDA approves expanded indication for UCB’s Briviact to treat paediatric patients

The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures in paediatric patients aged one month and above.

Japan approves AstraZeneca’s Forxiga for chronic kidney disease

Forxiga, a SGLT2 inhibitor, is the first medicine to secure approval for the treatment of CKD in Japan.

Pfizer-BioNTech seek FDA approval for Covid-19 booster dose

Pfizer and its partner BioNTech are seeking approval from the US Food and Drug Administration (FDA) for their booster dose of Covid-19 vaccine, Comirnaty, for individuals aged 16 years and above.

European Commission approves AbbVie’s Rinvoq for atopic dermatitis

The European Commission (EC) has approved AbbVie's Rinvoq (upadacitinib) to treat moderate to severe atopic dermatitis in adults and adolescents aged 12 years and above who are candidates for systemic therapy.

US FDA approves Pfizer-BioNTech’s Covid-19 vaccine

The US Food and Drug Administration (FDA) has fully approved Pfizer and BioNTech’s biologics license application (BLA) for their Covid-19 vaccine, Comirnaty, for individuals aged 16 years and above.

India approves EUA for Zydus Cadila’s ZyCoV-D Covid-19 vaccine

The Drugs Controller General of India (DCGI) has granted emergency use authorisation (EUA) for Zydus Cadila’s ZyCoV-D Covid-19 vaccine for adolescents aged 12 years and above.

EC approves Bristol Myers’ anti-BCMA CAR T-cell treatment for multiple myeloma

The European Commission (EC) has given conditional marketing authorization (CMA) to Bristol Myers Squibb’s (BMS) CAR T-cell therapy Abecma (idecabtagene vicleucel; ide-cel).